Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE(R) in Japan
(NASDAQ:CPRX), CORAL GABLES, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today reported that its sub-licensee in Japan, DyDo Pharma, Inc., (“DyDo”) has launched FIRDAPSE(R) (amifampridine) Tablets 10 mg in […]